Serum Adiposity-induced Biomarkers in Obese and Lean Children with Recently Diagnosed Autoimmune Type 1 Diabetes
Overview
Pediatrics
Affiliations
Background/objective: Obesity increases the risk of cardiovascular disease and diabetic complications in type 1 diabetes. Adipokines, which regulate obesity-induced inflammation, may contribute to this association. We compared serum adipokines and inflammatory cytokines in obese and lean children with new-onset autoimmune type 1 diabetes.
Subjects And Methods: We prospectively studied 32 lean and 18 obese children (age range: 2-18 yr) with new-onset autoimmune type 1 diabetes and followed them for up to 2 yr. Serum adipokines [leptin, total and high molecular weight (HMW) adiponectin, omentin, resistin, chemerin, visfatin], cytokines [interferon (IFN)-gamma, interleukin (IL)-10, IL-12, IL-6, IL-8, and tumor necrosis factor (TNF)-alpha] and C-reactive protein (CRP) were measured at a median of 7 wk after diagnosis (range: 3-16 wk).
Results: Lean children were 71.9% non-Hispanic White, 21.9% Hispanic, and 6.3% African-American, compared with 27.8, 55.6, and 16.7%, respectively, for obese children (p = 0.01). Compared with lean children, obese children had significantly higher serum leptin, visfatin, chemerin, TNF-alpha and CRP, and lower total adiponectin and omentin after adjustment for race/ethnicity and Tanner stage. African-American race was independently associated with higher leptin among youth ≥10 yr (p = 0.007). Leptin levels at onset positively correlated with hemoglobin A1c after 1-2 yr (p = 0.0001) independently of body mass index, race/ethnicity, and diabetes duration. Higher TNF-alpha was associated with obesity and female gender, after adjustment for race/ethnicity (p = 0.0003).
Conclusion: Obese children with new-onset autoimmune type 1 diabetes have a proinflammatory profile of circulating adipokines and cytokines that may contribute to the development of cardiovascular disease and diabetic complications.
Williams M, Grace C, Posgai A, McGrail K, Brusko M, Haller M BMJ Open Diabetes Res Care. 2025; 13(1.
PMID: 39755561 PMC: 11749058. DOI: 10.1136/bmjdrc-2024-004655.
Ullah A, Singla R, Batool Z, Cao D, Shen B Rev Endocr Metab Disord. 2024; 25(4):783-803.
PMID: 38709387 DOI: 10.1007/s11154-024-09884-y.
Kurpiewska E, Ciezki S, Jamiolkowska-Sztabkowska M, Polkowska A, Starosz A, Grubczak K Front Immunol. 2023; 14:1176403.
PMID: 37180128 PMC: 10174309. DOI: 10.3389/fimmu.2023.1176403.
Can type 1 diabetes be an unexpected complication of obesity?.
Oboza P, Ogarek N, Olszanecka-Glinianowicz M, Kocelak P Front Endocrinol (Lausanne). 2023; 14:1121303.
PMID: 37065759 PMC: 10102381. DOI: 10.3389/fendo.2023.1121303.
Ambroszkiewicz J, Chelchowska M, Mazur J, Rowicka G, Gajewska J J Clin Med. 2022; 11(14).
PMID: 35887780 PMC: 9320693. DOI: 10.3390/jcm11144013.